Norway
· Delayed Price · Currency is NOK Nykode Therapeutics AS Statistics
Total Valuation
OSL:NYKD has a market cap or net worth of NOK 847.71 million. The enterprise value is -424.25 million.
| Market Cap | 847.71M |
| Enterprise Value | -424.25M |
Important Dates
The last earnings date was Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OSL:NYKD has 326.55 million shares outstanding. The number of shares has increased by 8.66% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 326.55M |
| Shares Change (YoY) | +8.66% |
| Shares Change (QoQ) | +4.13% |
| Owned by Insiders (%) | 15.96% |
| Owned by Institutions (%) | 30.71% |
| Float | 149.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.15 |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.96 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.73 |
Financial Position
The company has a current ratio of 12.87, with a Debt / Equity ratio of 0.03.
| Current Ratio | 12.87 |
| Quick Ratio | 12.78 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -257.08 |
Financial Efficiency
Return on equity (ROE) is -25.25% and return on invested capital (ROIC) is -19.08%.
| Return on Equity (ROE) | -25.25% |
| Return on Assets (ROA) | -16.70% |
| Return on Invested Capital (ROIC) | -19.08% |
| Return on Capital Employed (ROCE) | -33.47% |
| Revenue Per Employee | 765,020 |
| Profits Per Employee | -3.24M |
| Employee Count | 139 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.24% in the last 52 weeks. The beta is 1.33, so OSL:NYKD's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -81.24% |
| 50-Day Moving Average | 2.30 |
| 200-Day Moving Average | 4.57 |
| Relative Strength Index (RSI) | 62.46 |
| Average Volume (20 Days) | 1,465,827 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OSL:NYKD had revenue of NOK 104.04 million and -441.04 million in losses. Loss per share was -1.36.
| Revenue | 104.04M |
| Gross Profit | 104.04M |
| Operating Income | -549.08M |
| Pretax Income | -517.07M |
| Net Income | -441.04M |
| EBITDA | -540.64M |
| EBIT | -549.08M |
| Loss Per Share | -1.36 |
Balance Sheet
The company has 1.31 billion in cash and 39.06 million in debt, giving a net cash position of 1.27 billion or 3.90 per share.
| Cash & Cash Equivalents | 1.31B |
| Total Debt | 39.06M |
| Net Cash | 1.27B |
| Net Cash Per Share | 3.90 |
| Equity (Book Value) | 1.55B |
| Book Value Per Share | 4.74 |
| Working Capital | 1.23B |
Cash Flow
In the last 12 months, operating cash flow was -581.90 million and capital expenditures -806,621, giving a free cash flow of -582.71 million.
| Operating Cash Flow | -581.90M |
| Capital Expenditures | -806,621 |
| Free Cash Flow | -582.71M |
| FCF Per Share | -1.78 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -527.75% |
| Pretax Margin | -496.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OSL:NYKD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.66% |
| Shareholder Yield | 31.89% |
| Earnings Yield | -52.03% |
| FCF Yield | -68.74% |
Stock Splits
The last stock split was on July 7, 2020. It was a forward split with a ratio of 5.
| Last Split Date | Jul 7, 2020 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
OSL:NYKD has an Altman Z-Score of 11.8.
| Altman Z-Score | 11.8 |
| Piotroski F-Score | n/a |